A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
暂无分享,去创建一个
F. Zoulim | P. Lampertico | M. Dandri | C. Scholtès | M. Maggioni | A. Sangiovanni | C. Neumann-Haefelin | V. Oberhardt | L. Allweiss | E. Degasperi | M. Anolli
[1] S. Zeuzem,et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study , 2022, Journal of Hepatology.
[2] F. Zoulim,et al. Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension. , 2022, Journal of hepatology.
[3] F. Tacke,et al. Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience , 2022, Journal of Hepatology.
[4] V. de Lédinghen,et al. Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort , 2022, Journal of Hepatology.
[5] F. Zoulim,et al. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. , 2021, Journal of hepatology.
[6] P. Lampertico,et al. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease , 2021, Gut.
[7] D. Kleiner,et al. Liver-resident bystander CD8+ T cells contribute to liver disease pathogenesis in chronic hepatitis D virus infection , 2021, Zeitschrift für Gastroenterologie.
[8] F. Zoulim,et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. , 2019, Journal of hepatology.
[9] W. Haefeli,et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection , 2018 .
[10] M. Manns,et al. Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta , 2014, Hepatology.
[11] M. Manns,et al. Hepatitis C and D, retroviruses and autoimmune manifestations. , 2001, Journal of autoimmunity.